The objective of this study is to evaluate the performance of urology residents at each training level in detecting prostate cancer with transrectal ultrasound-guided (TRUS) biopsy. The inclusion criteria were: (1) prostate-specific antigen (PSA) 4-10 ng/ml; and (2) 10-12 cores per biopsy session. Data from repeat biopsy sessions were excluded. Overall prostate cancer detection rate for 170 patients was 39.4%. PSA, digital rectal examination (DRE), and prostate volume were predictors of cancer detection. There were no significant differences in overall cancer detection rates, PSA, DRE, or prostate volume between resident levels. In conclusion, urology residents at all levels of training perform equally well at detecting cancer using TRUS prostate biopsy technology.
Introduction
Prostate cancer is the most commonly diagnosed cancer among men in the United States. The American Cancer Society estimated that the incidence of prostate cancer in 2003 would be 220, 900 men, which may result in up to 28 900 new prostate cancer deaths. 1 Since the introduction of transrectal ultrasound-guided (TRUS) biopsy of the prostate in 1989 by Hodge et al, 2 TRUS biopsy has become the gold standard to diagnose prostate cancer. Limited attention has been focused on the influence of training on prostate cancer detection rates. Gerstenbluth et al 3 reported that residents as a group had comparable prostate cancer detection rates to those reported in the literature. However, to the best of our knowledge, the impact of the year of residency training and experience on prostate cancer detection with TRUS has not been reported. In this study, we evaluated the performance of urology residents at all levels of training in an academic urology residency program to detect prostate cancer using TRUS biopsy technology.
Materials and methods
The medical records of 627 consecutive patients undergoing TRUS biopsy from July 1999 to December 2002 at the Dallas Veterans Administration Medical Center (DVAMC) were retrospectively reviewed. The indications for prostate biopsy included an abnormal digital rectal examination (DRE) and/or a prostate-specific antigen (PSA) level Z4 ng/ml. All biopsy sessions were performed using the Hitachi s EUB-525 ultrasound machine, the Hitachi s EUP-v53w end-fire ultrasound probe and the Bard s Biopty-Cut s spring-loaded 18-gauge biopsy needle. Biopsies were performed by urology residents at each level of training from Urology Year 1 to Urology Year 4 (hereafter referred to as 'U1 to U4', respectively). A senior level resident was present for up to five sessions to assist the junior resident in performing the TRUS-guided prostate biopsy. The number of prostate cores taken at each biopsy session was at the discretion of the resident performing the biopsy. All biopsy schemes included three paramedian and two to three laterally directed cores on each side of the prostate. Prostate volume was calculated using the following equation: 0.52 Â length Â width Â height. PSA density (PSAD) was the quotient of the total PSA level over the total prostate volume (cm 3 ). A biopsy was defined as positive only when adenocarcinoma was observed on final histological evaluation. The inclusion criteria for this study included: (1) PSA between 4 and 10 ng/ml; and (2) 10-12 biopsy cores taken per biopsy session. All data from repeat biopsy sessions were excluded from this analysis.
Age, PSA, prostate volume, and PSAD had skewed distributions and were transformed using the natural logarithm function. The w 2 test was used to evaluate differences between categorical variables. The one-way ANOVA test was used to evaluate differences in normally distributed variables between each year of resident training.
The Institutional Review Board of the DVAMC approved this study.
Results
Between July 1999 and December 2002, 627 consecutive patients underwent a total of 884 TRUS prostate biopsies. A total of 170 patients met the inclusion and exclusion criteria, and subsequently form the basis of this analysis. The overall cancer detection rate was 39.4% for the study group. For patients with a PSA 410 ng/ml undergoing their first biopsy session with 10-12 cores, the overall cancer detection rate was 78.5%. U4 residents performed a disproportionately lower number of the total biopsy sessions (5.5%) than U1 (37.1%), U2 (26.9%), and U3 (30.5%) residents. PSA, DRE, prostate volume, and PSAD were significant predictors of finding prostate cancer on logistic regression analysis (Table 1 ). There were no statistically significant differences in PSA level, DRE findings, prostate volume, or PSAD between residents at the U1 to U4 levels ( Table 2 ). Most importantly, there was no statistically significant difference in overall prostate cancer detection rates when stratified by resident level (Figure 1 ). Although we observed a trend towards a higher detection rate of prostate cancer by U1 residents vs U2 residents (43.5 vs 35.6%), the difference was not statistically significant (P-value ¼ 0.405, w 2 ).
Discussion
Prostate cancer is the most common noncutaneous malignancy in men. The best method currently available for the early diagnosis of clinically significant prostate cancer is screening with serum PSA followed by TRUS biopsy of the prostate for definitive diagnosis. 4 Many studies have investigated prebiopsy prognostic variables for cancer detection. PSA level, 5 prostate volume, 6-9 and DRE findings 10 are among the three most important variables predictive of biopsy outcome. Our findings echo these results. Additionally, the number of biopsy cores taken per biopsy session 11, 12 and the total number of repeat biopsy sessions in men with prior negative biopsies [13] [14] [15] are predictive of biopsy results. However, we controlled these variables by studying the results from men who underwent only one biopsy session with 10-12 cores.
Historically, urology residents have been actively involved in performing TRUS biopsies early in their residency training. Prior to this report, the ability of urology residents at different levels of training to detect prostate cancer using TRUS-guided biopsies had not yet been reported. In this study, a selected group of patients was identified for analysis in order to minimize selection bias and confounding factors. For example, we excluded patients with a PSA 410 ng/ml from this analysis because cancer detection rates in this group were uniformly higher (78.5%). With such a high cancer detection rate in this subgroup of patients, any difference in cancer detection rate between resident years might be difficult to identify.
The overall cancer detection rate in this study was 39.4%, which compared favorably with published reports of 29-39% cancer detection rates in similar patient cohorts. [6] [7] 13, [16] [17] [18] Besides a statistically insignificant trend towards a lower detection rate for U2 residents compared to U1 residents, there were no statistically significant differences in prebiopsy variables and overall cancer detection rates between residents at any level of training. One possible explanation is that TRUS biopsy is an essentially random process. Prostate cancer is almost always multifocal, and tumor foci tend to be randomly distributed in the gland. 19 In addition, routine transrectal ultrasonography does not accurately identify individual cancer foci. Although hypoechoic lesions on prostate ultrasound have been associated with cancer, most Resident Level Cancer Detection Rate (%) P = 0.854, Chi-square Figure 1 Cancer detection rates for resident levels U1 to U4, P ¼ 0.854, w 2 .
Detection of prostate cancer by urology residents JA Karam et al prostate cancer foci are actually isoechoic. Moreover, only a small fraction of hypoechoic areas within the prostate harbors cancer. 4, 20 Thus, the main utility of prostate ultrasound is to allow for a more thorough and even sampling of the prostate during the biopsy session. The observations made in our study indicate that after being properly introduced to the concept and technique of TRUS prostate biopsy, urology residents readily master the method and are able to detect the presence of prostate cancer with efficiency comparable to that reported in the literature. In patients with PSA levels between 4 and 10 ng/ml, undergoing first-time TRUS biopsies, prostate cancer detection is unlikely to be dependent upon the level of physician's experience.
Our study has several limitations. First, a prospective biopsy scheme was not used, which may have confounded our ability to compare cancer detection rates between residents. Second, the number of U4 residents performing biopsies was disproportionately low when compared to other resident levels. Lastly, our study was limited by its retrospective design, which made careful control and monitoring of data acquisition not possible. As a consequence, our patient population was heterogeneous. To overcome these limitations, we selected a homogeneous patient population with PSA levels between 4 and 10 undergoing their first biopsy session with 10-12 cores. In the present study, we did not analyze the complication rates following TRUS biopsies of the prostate performed by residents. However, due to the remarkably low overall rate of major complications such as urinary tract infections, sepsis, and significant bleeding after TRUS biopsy, it is unlikely that there were significant differences in the rate of these complications among residents with different levels of training. Nevertheless, there could be differences in the rates of other more subtle, procedure-related events such as pain, discomfort, and procedure duration that were not captured or analyzed in this study.
In conclusion, there was no learning curve associated with TRUS prostate biopsies. Residents at all levels of training perform equally well at detecting prostate cancer. These observations apply to patients with PSA levels between 4 and 10 ng/ml undergoing prostate biopsies for the first time with 10-12 cores.
